Legend Biotech Corporation (NASDAQ: LEGN) Stock Competitors & Peer Comparison
See LEGN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LEGN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LEGN | $19.89 | +5.69% | 3.7B | -29.25 | -$0.68 | N/A |
| VRTX | $522.81 | -0.74% | 132.8B | 27.49 | $19.03 | N/A |
| REGN | $758.27 | +1.03% | 78.1B | 16.62 | $45.63 | +0.49% |
| MRNA | $192.57 | -5.35% | 76.4B | -23.63 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $958.91 | -1.21% | 59.6B | 34.58 | $27.73 | N/A |
| RVMDW | $11.44 | +1.69% | 44.9B | -1.30 | -$8.82 | N/A |
| RVMD | $205.26 | +0.38% | 43.6B | -23.27 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $365.94 | +0.18% | 39.1B | 64.43 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
LEGN vs VRTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, VRTX has a market cap of 132.8B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while VRTX trades at $522.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas VRTX's P/E ratio is 27.49. In terms of profitability, LEGN's ROE is -0.09%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, LEGN is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
LEGN vs REGN Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, REGN has a market cap of 78.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while REGN trades at $758.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas REGN's P/E ratio is 16.62. In terms of profitability, LEGN's ROE is -0.09%, compared to REGN's ROE of +0.14%. Regarding short-term risk, LEGN is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
LEGN vs MRNA Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, MRNA has a market cap of 76.4B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while MRNA trades at $192.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas MRNA's P/E ratio is -23.63. In terms of profitability, LEGN's ROE is -0.09%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, LEGN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
LEGN vs VRNA Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas VRNA's P/E ratio is -102.80. In terms of profitability, LEGN's ROE is -0.09%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, LEGN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
LEGN vs ARGX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ARGX has a market cap of 59.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ARGX trades at $958.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ARGX's P/E ratio is 34.58. In terms of profitability, LEGN's ROE is -0.09%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, LEGN is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
LEGN vs RVMDW Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, RVMDW has a market cap of 44.9B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while RVMDW trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas RVMDW's P/E ratio is -1.30. In terms of profitability, LEGN's ROE is -0.09%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, LEGN is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
LEGN vs RVMD Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while RVMD trades at $205.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas RVMD's P/E ratio is -23.27. In terms of profitability, LEGN's ROE is -0.09%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, LEGN is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
LEGN vs SGEN Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas SGEN's P/E ratio is -57.19. In terms of profitability, LEGN's ROE is -0.09%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, LEGN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
LEGN vs ONC Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ONC has a market cap of 39.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ONC trades at $365.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ONC's P/E ratio is 64.43. In terms of profitability, LEGN's ROE is -0.09%, compared to ONC's ROE of +0.14%. Regarding short-term risk, LEGN is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
LEGN vs ALNY Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ALNY has a market cap of 33B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ALNY trades at $246.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ALNY's P/E ratio is 44.46. In terms of profitability, LEGN's ROE is -0.09%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, LEGN is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
LEGN vs ROIV Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ROIV has a market cap of 26.4B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ROIV trades at $36.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ROIV's P/E ratio is -34.79. In terms of profitability, LEGN's ROE is -0.09%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, LEGN is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
LEGN vs INSM Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, INSM has a market cap of 24.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while INSM trades at $114.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas INSM's P/E ratio is -27.77. In terms of profitability, LEGN's ROE is -0.09%, compared to INSM's ROE of -1.11%. Regarding short-term risk, LEGN is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
LEGN vs BNTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, BNTX has a market cap of 24.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while BNTX trades at $98.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas BNTX's P/E ratio is -12.75. In terms of profitability, LEGN's ROE is -0.09%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, LEGN is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
LEGN vs INCY Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, INCY has a market cap of 24.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while INCY trades at $121.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas INCY's P/E ratio is 16.31. In terms of profitability, LEGN's ROE is -0.09%, compared to INCY's ROE of +0.30%. Regarding short-term risk, LEGN is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
LEGN vs UTHR Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while UTHR trades at $541.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas UTHR's P/E ratio is 19.39. In terms of profitability, LEGN's ROE is -0.09%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, LEGN is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
LEGN vs GMAB Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, GMAB has a market cap of 21.9B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while GMAB trades at $35.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas GMAB's P/E ratio is 26.88. In terms of profitability, LEGN's ROE is -0.09%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, LEGN is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
LEGN vs BGNE Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas BGNE's P/E ratio is -22.55. In terms of profitability, LEGN's ROE is -0.09%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, LEGN is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
LEGN vs DNA-WT Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, LEGN's ROE is -0.09%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, LEGN is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
LEGN vs EXEL Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while EXEL trades at $58.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas EXEL's P/E ratio is 16.69. In terms of profitability, LEGN's ROE is -0.09%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, LEGN is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check EXEL's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
LEGN vs JAZZ Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, JAZZ has a market cap of 14.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while JAZZ trades at $231.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas JAZZ's P/E ratio is 8.63. In terms of profitability, LEGN's ROE is -0.09%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, LEGN is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
LEGN vs NBIX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, NBIX has a market cap of 14.3B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while NBIX trades at $141.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas NBIX's P/E ratio is 20.50. In terms of profitability, LEGN's ROE is -0.09%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, LEGN is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
LEGN vs ASND Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ASND trades at $227.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ASND's P/E ratio is -94.14. In terms of profitability, LEGN's ROE is -0.09%, compared to ASND's ROE of +1.90%. Regarding short-term risk, LEGN is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ASND's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
LEGN vs SMMT Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, SMMT has a market cap of 13.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while SMMT trades at $16.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas SMMT's P/E ratio is -15.10. In terms of profitability, LEGN's ROE is -0.09%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, LEGN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
LEGN vs HALO Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, HALO has a market cap of 13.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while HALO trades at $110.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas HALO's P/E ratio is 20.60. In terms of profitability, LEGN's ROE is -0.09%, compared to HALO's ROE of +1.81%. Regarding short-term risk, LEGN is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
LEGN vs BBIO Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, BBIO has a market cap of 12.9B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while BBIO trades at $65.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas BBIO's P/E ratio is -17.59. In terms of profitability, LEGN's ROE is -0.09%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, LEGN is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
LEGN vs KRTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas KRTX's P/E ratio is -28.09. In terms of profitability, LEGN's ROE is -0.09%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, LEGN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check KRTX's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
LEGN vs TWST Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, TWST has a market cap of 12B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while TWST trades at $193.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas TWST's P/E ratio is -86.95. In terms of profitability, LEGN's ROE is -0.09%, compared to TWST's ROE of -0.30%. Regarding short-term risk, LEGN is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check TWST's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
LEGN vs MDGL Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, MDGL has a market cap of 11.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while MDGL trades at $503.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas MDGL's P/E ratio is -39.37. In terms of profitability, LEGN's ROE is -0.09%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, LEGN is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check MDGL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
LEGN vs BMRN Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while BMRN trades at $60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas BMRN's P/E ratio is 28.85. In terms of profitability, LEGN's ROE is -0.09%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, LEGN is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check BMRN's competition here
10x Genomics, Inc. (NASDAQ: TXG)
LEGN vs TXG Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, TXG has a market cap of 11.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while TXG trades at $90.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas TXG's P/E ratio is -153.15. In terms of profitability, LEGN's ROE is -0.09%, compared to TXG's ROE of -0.09%. Regarding short-term risk, LEGN is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check TXG's competition here
Bio-Techne Corporation (NASDAQ: TECH)
LEGN vs TECH Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while TECH trades at $72.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas TECH's P/E ratio is 37.36. In terms of profitability, LEGN's ROE is -0.09%, compared to TECH's ROE of +0.09%. Regarding short-term risk, LEGN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
LEGN vs RNAM Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas RNAM's P/E ratio is -17.39. In terms of profitability, LEGN's ROE is -0.09%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, LEGN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check RNAM's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
LEGN vs IBRX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, IBRX has a market cap of 9.9B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while IBRX trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas IBRX's P/E ratio is -9.73. In terms of profitability, LEGN's ROE is -0.09%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, LEGN is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check IBRX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
LEGN vs KRYS Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while KRYS trades at $332.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas KRYS's P/E ratio is 41.67. In terms of profitability, LEGN's ROE is -0.09%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, LEGN is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
LEGN vs RXDX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas RXDX's P/E ratio is -56.47. In terms of profitability, LEGN's ROE is -0.09%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, LEGN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check RXDX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
LEGN vs AXSM Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, AXSM has a market cap of 9.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while AXSM trades at $184.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas AXSM's P/E ratio is -48.14. In terms of profitability, LEGN's ROE is -0.09%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, LEGN is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
LEGN vs ARWR Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ARWR has a market cap of 9.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ARWR trades at $65.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ARWR's P/E ratio is -29.09. In terms of profitability, LEGN's ROE is -0.09%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, LEGN is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ARWR's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
LEGN vs KYMR Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, KYMR has a market cap of 9.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while KYMR trades at $111.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas KYMR's P/E ratio is -34.93. In terms of profitability, LEGN's ROE is -0.09%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, LEGN is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check KYMR's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
LEGN vs NUVL Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas NUVL's P/E ratio is -21.79. In terms of profitability, LEGN's ROE is -0.09%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, LEGN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check NUVL's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
LEGN vs PTGX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, PTGX has a market cap of 9.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while PTGX trades at $140.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas PTGX's P/E ratio is 136.79. In terms of profitability, LEGN's ROE is -0.09%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, LEGN is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check PTGX's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
LEGN vs CRNX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CRNX's P/E ratio is -16.86. In terms of profitability, LEGN's ROE is -0.09%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, LEGN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
LEGN vs IMGN Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas IMGN's P/E ratio is -111.55. In terms of profitability, LEGN's ROE is -0.09%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, LEGN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check IMGN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
LEGN vs CAI Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CAI has a market cap of 8.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CAI trades at $30.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CAI's P/E ratio is 86.06. In terms of profitability, LEGN's ROE is -0.09%, compared to CAI's ROE of +0.19%. Regarding short-term risk, LEGN is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CAI's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
LEGN vs TGTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while TGTX trades at $55.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas TGTX's P/E ratio is 20.21. In terms of profitability, LEGN's ROE is -0.09%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, LEGN is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
LEGN vs BPMC Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas BPMC's P/E ratio is -51.58. In terms of profitability, LEGN's ROE is -0.09%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, LEGN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
LEGN vs APGE Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas APGE's P/E ratio is -31.19. In terms of profitability, LEGN's ROE is -0.09%, compared to APGE's ROE of -0.30%. Regarding short-term risk, LEGN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check APGE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
LEGN vs PCVX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while PCVX trades at $56.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas PCVX's P/E ratio is -7.46. In terms of profitability, LEGN's ROE is -0.09%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, LEGN is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check PCVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
LEGN vs CYTK Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CYTK trades at $65.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CYTK's P/E ratio is -9.13. In terms of profitability, LEGN's ROE is -0.09%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, LEGN is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CYTK's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
LEGN vs CERE Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CERE's P/E ratio is -16.47. In terms of profitability, LEGN's ROE is -0.09%, compared to CERE's ROE of -0.72%. Regarding short-term risk, LEGN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CERE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
LEGN vs PRAX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, PRAX has a market cap of 8.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while PRAX trades at $291.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas PRAX's P/E ratio is -22.52. In terms of profitability, LEGN's ROE is -0.09%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, LEGN is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
LEGN vs SYRE Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, SYRE has a market cap of 7.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while SYRE trades at $89.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas SYRE's P/E ratio is -45.66. In terms of profitability, LEGN's ROE is -0.09%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, LEGN is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
LEGN vs MTSR Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas MTSR's P/E ratio is -23.58. In terms of profitability, LEGN's ROE is -0.09%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, LEGN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
LEGN vs IONS Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while IONS trades at $44.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas IONS's P/E ratio is -13.65. In terms of profitability, LEGN's ROE is -0.09%, compared to IONS's ROE of -1.11%. Regarding short-term risk, LEGN is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check IONS's competition here
Abivax S.A. (NASDAQ: ABVX)
LEGN vs ABVX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ABVX has a market cap of 7.3B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ABVX trades at $99.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ABVX's P/E ratio is -18.84. In terms of profitability, LEGN's ROE is -0.09%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, LEGN is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ABVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
LEGN vs IMVT Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, IMVT has a market cap of 7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while IMVT trades at $33.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas IMVT's P/E ratio is -11.98. In terms of profitability, LEGN's ROE is -0.09%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, LEGN is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check IMVT's competition here
Merus N.V. (NASDAQ: MRUS)
LEGN vs MRUS Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas MRUS's P/E ratio is -17.05. In terms of profitability, LEGN's ROE is -0.09%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, LEGN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check MRUS's competition here
Belite Bio, Inc (NASDAQ: BLTE)
LEGN vs BLTE Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, BLTE has a market cap of 6.8B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while BLTE trades at $169.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas BLTE's P/E ratio is -90.81. In terms of profitability, LEGN's ROE is -0.09%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, LEGN is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check BLTE's competition here
Arcellx, Inc. (NASDAQ: ACLX)
LEGN vs ACLX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ACLX's P/E ratio is -28.27. In terms of profitability, LEGN's ROE is -0.09%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, LEGN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ACLX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
LEGN vs IOVA Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, IOVA has a market cap of 6.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while IOVA trades at $14.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas IOVA's P/E ratio is -20.30. In terms of profitability, LEGN's ROE is -0.09%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, LEGN is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check IOVA's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
LEGN vs RETA Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas RETA's P/E ratio is -66.29. In terms of profitability, LEGN's ROE is -0.09%, compared to RETA's ROE of +0.47%. Regarding short-term risk, LEGN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check RETA's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
LEGN vs RYTM Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, RYTM has a market cap of 6.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while RYTM trades at $95.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas RYTM's P/E ratio is -30.62. In terms of profitability, LEGN's ROE is -0.09%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, LEGN is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check RYTM's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
LEGN vs CNTA Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CNTA's P/E ratio is -22.63. In terms of profitability, LEGN's ROE is -0.09%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, LEGN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
LEGN vs LGND Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while LGND trades at $312.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas LGND's P/E ratio is 34.29. In terms of profitability, LEGN's ROE is -0.09%, compared to LGND's ROE of +0.20%. Regarding short-term risk, LEGN is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check LGND's competition here
CG Oncology Inc. (NASDAQ: CGON)
LEGN vs CGON Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CGON trades at $70.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CGON's P/E ratio is -26.35. In terms of profitability, LEGN's ROE is -0.09%, compared to CGON's ROE of -0.25%. Regarding short-term risk, LEGN is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CGON's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
LEGN vs KOD Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, KOD has a market cap of 5.9B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while KOD trades at $94.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas KOD's P/E ratio is -22.73. In terms of profitability, LEGN's ROE is -0.09%, compared to KOD's ROE of -2.73%. Regarding short-term risk, LEGN is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check KOD's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
LEGN vs SRRK Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while SRRK trades at $48.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas SRRK's P/E ratio is -14.03. In terms of profitability, LEGN's ROE is -0.09%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, LEGN is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
LEGN vs CDTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CDTX's P/E ratio is -19.77. In terms of profitability, LEGN's ROE is -0.09%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, LEGN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
LEGN vs ABCM Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, LEGN's ROE is -0.09%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, LEGN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
LEGN vs ISEE Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ISEE's P/E ratio is -22.44. In terms of profitability, LEGN's ROE is -0.09%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, LEGN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
LEGN vs TVTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, TVTX has a market cap of 5.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while TVTX trades at $58.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas TVTX's P/E ratio is -130.80. In terms of profitability, LEGN's ROE is -0.09%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, LEGN is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check TVTX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
LEGN vs COGT Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while COGT trades at $32.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas COGT's P/E ratio is -15.18. In terms of profitability, LEGN's ROE is -0.09%, compared to COGT's ROE of -0.73%. Regarding short-term risk, LEGN is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
LEGN vs PTCT Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while PTCT trades at $64.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas PTCT's P/E ratio is -27.80. In terms of profitability, LEGN's ROE is -0.09%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, LEGN is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
LEGN vs CRSP Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CRSP trades at $55.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CRSP's P/E ratio is -11.62. In terms of profitability, LEGN's ROE is -0.09%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, LEGN is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CRSP's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
LEGN vs APLS Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas APLS's P/E ratio is 38.35. In terms of profitability, LEGN's ROE is -0.09%, compared to APLS's ROE of +0.40%. Regarding short-term risk, LEGN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check APLS's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
LEGN vs MIRM Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, MIRM has a market cap of 5.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while MIRM trades at $85.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas MIRM's P/E ratio is -5.87. In terms of profitability, LEGN's ROE is -0.09%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, LEGN is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check MIRM's competition here
Erasca, Inc. (NASDAQ: ERAS)
LEGN vs ERAS Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ERAS trades at $14.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ERAS's P/E ratio is -15.76. In terms of profitability, LEGN's ROE is -0.09%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, LEGN is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
LEGN vs MANE Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, MANE has a market cap of 5.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while MANE trades at $121.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas MANE's P/E ratio is -38.65. In terms of profitability, LEGN's ROE is -0.09%, compared to MANE's ROE of -0.38%. Regarding short-term risk, LEGN is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check MANE's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
LEGN vs DFTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while DFTX trades at $38.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas DFTX's P/E ratio is N/A. In terms of profitability, LEGN's ROE is -0.09%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, LEGN is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check DFTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
LEGN vs ORKA Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ORKA has a market cap of 5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ORKA trades at $83.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ORKA's P/E ratio is -42.93. In terms of profitability, LEGN's ROE is -0.09%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, LEGN is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ORKA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
LEGN vs DNTH Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while DNTH trades at $88.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas DNTH's P/E ratio is -21.22. In terms of profitability, LEGN's ROE is -0.09%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, LEGN is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check DNTH's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
LEGN vs TERN Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas TERN's P/E ratio is -51.41. In terms of profitability, LEGN's ROE is -0.09%, compared to TERN's ROE of -0.20%. Regarding short-term risk, LEGN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check TERN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
LEGN vs ADPT Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ADPT trades at $28.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ADPT's P/E ratio is -70.49. In terms of profitability, LEGN's ROE is -0.09%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, LEGN is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
LEGN vs FOLD Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas FOLD's P/E ratio is -161.00. In terms of profitability, LEGN's ROE is -0.09%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, LEGN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
LEGN vs AKRO Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas AKRO's P/E ratio is -14.57. In terms of profitability, LEGN's ROE is -0.09%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, LEGN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
LEGN vs ALPN Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ALPN's P/E ratio is -101.52. In terms of profitability, LEGN's ROE is -0.09%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, LEGN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ALPN's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
LEGN vs ABCL Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, ABCL has a market cap of 4.5B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while ABCL trades at $14.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas ABCL's P/E ratio is -27.02. In terms of profitability, LEGN's ROE is -0.09%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, LEGN is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check ABCL's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
LEGN vs EWTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while EWTX trades at $40.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas EWTX's P/E ratio is -21.95. In terms of profitability, LEGN's ROE is -0.09%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, LEGN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check EWTX's competition here
Opthea Limited (NASDAQ: OPT)
LEGN vs OPT Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas OPT's P/E ratio is -1.52. In terms of profitability, LEGN's ROE is -0.09%, compared to OPT's ROE of +1.18%. Regarding short-term risk, LEGN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
LEGN vs PRTC Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas PRTC's P/E ratio is -3.78. In terms of profitability, LEGN's ROE is -0.09%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, LEGN is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
LEGN vs MRTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas MRTX's P/E ratio is -4.82. In terms of profitability, LEGN's ROE is -0.09%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, LEGN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check MRTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
LEGN vs TNGX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while TNGX trades at $24.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas TNGX's P/E ratio is -30.06. In terms of profitability, LEGN's ROE is -0.09%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, LEGN is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check TNGX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
LEGN vs RLAY Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while RLAY trades at $18.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas RLAY's P/E ratio is -11.50. In terms of profitability, LEGN's ROE is -0.09%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, LEGN is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check RLAY's competition here
Celcuity Inc. (NASDAQ: CELC)
LEGN vs CELC Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CELC trades at $79.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CELC's P/E ratio is -18.49. In terms of profitability, LEGN's ROE is -0.09%, compared to CELC's ROE of -3.51%. Regarding short-term risk, LEGN is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
LEGN vs CPRX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CPRX's P/E ratio is 17.49. In terms of profitability, LEGN's ROE is -0.09%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, LEGN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CPRX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
LEGN vs VKTX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while VKTX trades at $32.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas VKTX's P/E ratio is -7.00. In terms of profitability, LEGN's ROE is -0.09%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, LEGN is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for LEGN.Check VKTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
LEGN vs PBLS Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, PBLS has a market cap of 3.8B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while PBLS trades at $32.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas PBLS's P/E ratio is -17.18. In terms of profitability, LEGN's ROE is -0.09%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, LEGN is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check PBLS's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
LEGN vs RYZB Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas RYZB's P/E ratio is -57.86. In terms of profitability, LEGN's ROE is -0.09%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, LEGN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
LEGN vs CBAY Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas CBAY's P/E ratio is -32.81. In terms of profitability, LEGN's ROE is -0.09%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, LEGN is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check CBAY's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
LEGN vs TLX Comparison October 2026
Legend Biotech Corporation (NASDAQ: LEGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LEGN stands at 3.7B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, LEGN is priced at $19.89 on the NASDAQ, while TLX trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LEGN currently has a P/E ratio of -29.25, whereas TLX's P/E ratio is 114.51. In terms of profitability, LEGN's ROE is -0.09%, compared to TLX's ROE of +0.07%. Regarding short-term risk, LEGN is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for LEGN.Check TLX's competition here